JB Chemicals and Pharmaceuticals stock reports Q1 growth with margin gains

JB Chemicals and Pharmaceuticals stock stood at INR 2,408.90 on the NSE on September 23, 2026, 4.6 percent below its 52-week high of INR 2,525.50. The companys Q1 FY27 operating figures add substance to the valuation story, with base business revenue up 10 percent year over year.

Q1 margin expands sharply

According to DSIJ in its September 24, 2026 report, JB Pharmas base business EBITDA rose 34 percent in Q1 FY27. The EBITDA margin reached 35.3 percent, compared with 28.8 percent a year earlier.

The margin gain of 6.5 percentage points is the clearest operating comparison in the current data. It indicates that profit conversion improved faster than revenue, a useful distinction for investors assessing whether growth is translating into operating leverage.

Domestic and international sales grow

DSIJ reported that JB Pharmas domestic business grew 13 percent in Q1 FY27, while international business increased 12 percent. The two figures show a broadly distributed growth profile rather than reliance on a single geography.

The companys base business also delivered the 10 percent revenue increase in the quarter. Together, the revenue and EBITDA figures point to an operating picture in which margin expansion exceeded top-line growth.

Stock stays below yearly high

On the NSE, the INR 2,408.90 price on September 23, 2026, was 4.6 percent below the 52-week high of INR 2,525.50 and 47.0 percent above the 52-week low of INR 1,638.50. The range places the stock closer to its upper end than its yearly low.

For investors, the central measure is the combination of 10 percent base business revenue growth and a 35.3 percent EBITDA margin in Q1 FY27. The next reported period will show whether the 6.5 percentage point margin improvement continues.